B of A Securities Initiates Coverage On Neumora Therapeutics with Buy Rating, Announces Price Target of $18
Portfolio Pulse from Benzinga Newsdesk
B of A Securities analyst Geoff Meacham has initiated coverage on Neumora Therapeutics (NASDAQ:NMRA) with a Buy rating and a price target of $18.
October 10, 2023 | 12:31 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Neumora Therapeutics has been given a Buy rating and a price target of $18 by B of A Securities.
The Buy rating and price target of $18 announced by B of A Securities for Neumora Therapeutics is a positive signal for the company. This could potentially attract more investors, driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100